On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor

被引:0
作者
Christopoulos, A
Pierce, TL
Sorman, JL
El-Fakahany, EE [1 ]
机构
[1] Univ Minnesota, Sch Med, Div Neurosci Res Psychiat, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Med, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We investigated the molecular nature of the interaction between the functionally selective M-1 muscarinic acetylcholine receptor (mAChR) agonist xanomeline and the human M-1 mAChR expressed in Chinese hamster ovary (CHO) cells. In contrast to the non-subtype-selective agonist carbachol, xanomeline demonstrated M-1 mAChR binding that was resistant to extensive washout, resulting in a significant reduction in apparent N-[H-3]methylscopolamine saturation binding affinity in intact cells. Functional assays, using both M-1 mAChR-mediated phosphoinositide hydrolysis and activation of neuronal nitric oxide synthase, confirmed that this persistent binding resulted in elevated basal levels of system activity. Furthermore, this phenomenon could be reversed by the addition of the antagonist atropine. However, pharmacological analysis of the inhibition by atropine of xanomeline-mediated functional responses indicated a possible element of noncompetitive behavior that was not evident in several kinetic and equilibrium binding experimental paradigms. Taken together, our findings indicate for the first time a novel mode of interaction between an mAChR agonist and the M-1 mAChR, which may involve unusually avid binding of xanomeline to the receptor. This yields a fraction of added agonist that is retained at the level of the receptor compartment to persistently bind to and activate the receptor subsequent to washout. The results of the current study suggest that elucidation of the mechanism or mechanisms of interaction of xanomeline with the M-1 mAChR is particularly important in relation to the potential therapeutic use of this agent in the treatment of Alzheimer's disease.
引用
收藏
页码:1120 / 1130
页数:11
相关论文
共 29 条
[1]   SOME QUANTITATIVE USES OF DRUG ANTAGONISTS [J].
ARUNLAKSHANA, O ;
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01) :48-58
[2]   Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease [J].
Bodick, NC ;
Offen, WW ;
Levey, AI ;
Cutler, NR ;
Gauthier, SG ;
Satlin, A ;
Shannon, HE ;
Tollefson, GD ;
Rasmussen, K ;
Bymaster, FP ;
Hurley, DJ ;
Potter, WZ ;
Paul, SM .
ARCHIVES OF NEUROLOGY, 1997, 54 (04) :465-473
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   NITRIC-OXIDE MEDIATES GLUTAMATE-LINKED ENHANCEMENT OF CGMP LEVELS IN THE CEREBELLUM [J].
BREDT, DS ;
SNYDER, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :9030-9033
[5]  
Bymaster FP, 1997, DRUG DEVELOP RES, V40, P158, DOI 10.1002/(SICI)1098-2299(199702)40:2<158::AID-DDR6>3.3.CO
[6]  
2-6
[7]   Novel persistent activation of muscarinic M-1 receptors by xanomeline [J].
Christopoulos, A ;
ElFakahany, EE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 334 (01) :R3-R4
[8]  
Clark RB, 1996, MOL PHARMACOL, V49, P182
[9]   Exosites: Their current status, and their relevance to the duration of action of long-acting beta(2)-adrenoceptor agonists [J].
Coleman, RA ;
Johnson, M ;
Nials, AT ;
Vardey, CJ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (09) :324-330
[10]   ATTENUATION OF MUSCARINIC RECEPTOR-G-PROTEIN INTERACTION IN ALZHEIMER-DISEASE [J].
FERRARIDILEO, G ;
MASH, DC ;
FLYNN, DD .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 24 (01) :69-91